A Phase 3 interventional study of FluBlok Influenza Vaccination and TIV (Fluzone) Influenza Vaccination in Influenza, sponsored by Protein Sciences Corporation. Completed at 5 sites in United States. Open to participants aged 50 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-07-27.
Sponsored by Protein Sciences Corporation · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing FluBlok in Influenza, Human — none open to participants now, none under way, none of them phase 3. FluBlok · Influenza, Human.
Among the 11 studies testing FluBlok in Influenza, Human, this one is the 7th largest by enrollment, is one of 2 that started in 2007, is one of 3 in phase 3, and was the 3rd registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →None of the 11 studies testing FluBlok in Influenza, Human is open now. The open studies under Influenza, Human, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 50 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 4 · Phase 4 5
First in 2004; this study’s year is marked. 2 started in 2007.
This study's enrollment of 602 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 606 across the 11 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 8 most frequent:
Protein Sciences Corporation is the lead sponsor of 12 studies on the registry; none are open to participants now.
12 studies in Influenza, Human by Protein Sciences Corporation: none open now, none under way, none of them phase 3. Of 12 finished, 8 (67%) have results posted.
Among the 12 studies in Influenza, Human by Protein Sciences Corporation, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2007, is one of 6 in phase 3, and was the 4th registered.
Protein Sciences Corporation’s Influenza, Human studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing FluBlok in Influenza, Human, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Protein Sciences Corporation’s 12 in Influenza, Human:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate and compare the safety, reactogenicity, immunogenicity, relative efficacy and effectiveness of FluBlok to a licensed trivalent influenza vaccine (TIV)in healthy adults age 50-64 years.
Annual influenza epidemics are associated with serious excess morbidity and mortality, particularly among the elderly. Licensed trivalent inactivated influenza vaccines (TIVs) have been shown to reduce hospitalization and death following influenza in this vulnerable population, but their efficacy is lower than that observed in younger, healthy populations. In addition, recent studies have questioned the level of effectiveness of TIV in the elderly, suggesting that cohort studies have overestimated the benefits of immunization with current TIV formulations in this age group. In view of these considerations, it is widely accepted that improved and alternative vaccines are needed for control of seasonal and pandemic influenza.
Currently available TIVs are prepared from viruses that are grown in embryonated hens' eggs. Alternative substrates for vaccine production are desirable in order to reduce the vulnerability of and to expand influenza vaccine supply. Recombinant DNA techniques allow for expression of the influenza hemagglutinin (rHA) by baculovirus vectors in insect cell cultures. Advantages of this technique include speed of production, absence of egg protein, and a highly purified product. Previous studies among healthy younger and older adults have confirmed that rHA vaccines are safe, well tolerated and immunogenic at dosages up to nine times higher than those contained in TIV. Dose-related increases in serum antibody levels after immunization also were observed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 135μg total
Biological: FluBlok Influenza Vaccination
Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 45μg total (Fluzone, sanofi pasteur)
Biological: TIV (Fluzone) Influenza Vaccination
0.5mL dose for intramuscular injection
Also known as: FluBlok, rHA, rHA0, recombinant hemagglutinin
0.5mL dose for intramuscular injection
Also known as: Fluzone, TIV
Number of Participants With Reactogenicity (Solicited) Adverse Events (AEs)
Solicited reactogenicity events included injection site pain, bruising, erythema and swelling. Solicited systemic AEs included fatigue, chills, arthralgias, myalgias, headache and nausea.
Time frame: Reactogenicity days 0-7 following immunization; other AEs days 0-28 following immunization
Evaluation and Comparison of Immunogenicity of FluBlok and TIV in Healthy Adults 50-64 Years of Age.
Immunogenicity was assessed by measuring the difference in values in Hemagglutination-Inhibition Assay (HAI) titers in participants from Day 0 to Day 28, using Geometric Mean Titers (GMTs). The GMTs from the FluBlok and TIV groups were then compared.
Time frame: Day 0 and Day 28
Percentage of Participants With Seroconversion
Percentage of participants with greater than or equal to a 4-fold rise in Hemagglutination-Inhibition Assay (HAI) titer over Day 0 at Day 28 following immunization
Time frame: Day 28 following immunization at Day 0
Percentage of Participants With Seroprotection
Percentage of participants with (HAI titer greater than or equal to 40) at Day 28
Time frame: Day 28 following immunization at Day 0
Subjects 50 - \<64 years of age were screened in participating outpatient clinics for eligibility within 30 days of randomization during the 2007 influenza season.
| Milestone | FluBlok | TIV (Fluzone) |
|---|---|---|
| Started | 300 | 302 |
| Completed | 299 | 300 |
| Not completed | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
Immunogenicity was assessed by measuring the difference in values in Hemagglutination-Inhibition Assay (HAI) titers in participants from Day 0 to Day 28, using Geometric Mean Titers (GMTs). The GMTs from the FluBlok and TIV groups were then compared.
| HAI Titers | FluBlok | TIV (Fluzone) |
|---|---|---|
| A/Solomon Islands (H1N1) - Day 0 | 28.71 (25.59 to 32.21) | 27.77 (25.07 to 30.76) |
| A/Solomon Islands (H1N1) - Day 28 | 181.34 (159.61 to 206.02) | 139.74 (124.64 to 156.66) |
| A/Wisconsin (H3N2) - Day 0 | 18.57 (16.37 to 21.06) | 18.20 (16.07 to 20.62) |
| A/Wisconsin (H3N2) - Day 28 | 105.41 (91.01 to 122.09) | 60.88 (53.58 to 69.18) |
| B/Malaysia - Day 0 | 48.49 (43.38 to 54.19) | 49.18 (43.77 to 55.25) |
| B/Malaysia - Day 28 | 110.93 (100.07 to 122.97) | 116.03 (104.16 to 129.25) |
Solicited reactogenicity events included injection site pain, bruising, erythema and swelling. Solicited systemic AEs included fatigue, chills, arthralgias, myalgias, headache and nausea.
| participants | FluBlok | TIV (Fluzone) |
|---|---|---|
| Fatigue | 40 | 62 |
| Chills | 12 | 15 |
| Arthralgias | 15 | 19 |
| Myalgia | 40 | 63 |
| Headache | 59 | 63 |
| Nausea | 13 | 15 |
| Injection Site Pain | 154 | 165 |
| Injection Site Bruising | 16 | 14 |
| Injection Site Erythema | 24 | 25 |
| Injection Site Swelling | 25 | 30 |
Percentage of participants with greater than or equal to a 4-fold rise in Hemagglutination-Inhibition Assay (HAI) titer over Day 0 at Day 28 following immunization
| Percentage of participants | FluBlok | TIV (Fluzone) |
|---|---|---|
| A/Solomon Islands (H1N1) | 72 (66.8 to 77.2) | 66 (60.6 to 71.5) |
| A/Wisconsin (H3N2) | 61 (55.4 to 66.8) | 44 (38.0 to 69.2) |
| B/Malaysia | 41 (35.2 to 46.6) | 41 (35.5 to 46.8) |
Percentage of participants with (HAI titer greater than or equal to 40) at Day 28
| Percentage of participants | FluBlok | TIV (Fluzone) |
|---|---|---|
| Influenza A/Solomon Islands (H1N1) | 96 (93.5 to 98.1) | 96 (92.8 to 97.7) |
| Influenza A/Wisconsin (H3N2) | 85 (80.8 to 89.1) | 75 (69.9 to 79.9) |
| Influenza B/Malaysia | 93 (89.5 to 95.6) | 94 (91.1 to 96.7) |
Collected over All AEs - 28 days following immunization; SAEs for duration of influenza season.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FluBlok | — | 1/300 (0.3%) | 4/300 (1.3%) |
| TIV (Fluzone) | — | 0/302 (0%) | 9/302 (3%) |
| Event | FluBlok | TIV (Fluzone) |
|---|---|---|
| Vasovagal SyncopeCardiac disorders | 1/300 | 0/302 |
| Event | FluBlok | TIV (Fluzone) |
|---|---|---|
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 4/300 | 9/302 |
| Age, Categorical(Participants) | FluBlok | TIV (Fluzone) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 300 | 302 | 602 |
| >=65 years | 0 | 0 | 0 |
| Age Continuous(years) | FluBlok | TIV (Fluzone) | Total |
|---|---|---|---|
| Mean | 55.9 ± 3.71 | 55.7 ± 3.64 | 55.8 ± 3.67 |
| Sex: Female, Male(Participants) | FluBlok | TIV (Fluzone) | Total |
|---|---|---|---|
| Female | 187 | 192 | 379 |
| Male | 113 | 110 | 223 |
| Region of Enrollment(participants) | FluBlok | TIV (Fluzone) | Total |
|---|---|---|---|
| United States | 300 | 302 | 602 |
The record gives a start of Sep 2007, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: FluBlok
Protein Sciences Corporation